Total revenue increased 23% to $12.0 million. Core non-COVID-19 product sales increased 38% Y-Y, driving overall Q2 2021 product sales to $11.4 million versus $9.5 million a year ago MONMOUTH JUNCTION, N.J., Aug. 3, 2021 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery […]
Financial
Append Medical Completes $7.4M Million Series A Round
Funding Will Support the Company’s First Clinical Trial on its Path to Regulatory Clearance OR YEHUDA, Israel, Aug. 4, 2021 /PRNewswire/ — Append Medical, developer of the first no-implant minimally invasive solution for transcatheter Left Atrial Appendage (LAA) exclusion, today announced the completion of a $7.4 million Series A financing round. The round will enable Append […]
CINDE announces: Baylis Medical Opens MedTech Facility in Costa Rica
Headquartered in Canada, the company will manufacture in Costa Rica cardiovascular products to serve global markets. The 2.800 mts2 facility will be in La Lima Free Zone. CARTAGO, Costa Rica, Aug. 3, 2021 /PRNewswire/ — Baylis Medical, a Canadian company and leader in the development and commercialization of innovative medical devices in cardiology, announced today its […]
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 30, 2021 it granted stock options to purchase an aggregate of 258,750 shares of common stock to 15 new employees, whose employment commenced in July 2021, as a material inducement to […]
ESPERION Reports Second Quarter 2021 Financial Results and Provides Company Update
– U.S. Net Product Revenue of NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets Grew 67% Sequentially to $10.6 Million – – Growth Driven by Increase in Demand and Substantial Improvement in Net Price – – Prescriptions Grew 28% During the Quarter; More Than 47,800 Patients Have Filled a Prescription for […]
LivaNova Announces Offering of Ordinary Shares
LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it has commenced an underwritten offering of $300 million of its ordinary shares. LivaNova also intends to grant the underwriters of the offering a 30-day option to acquire up to an additional 15% of the ordinary shares […]
Edwards Lifesciences Reports Second Quarter Results
IRVINE, Calif., July 29, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2021. Second Quarter Highlights and 2021 Outlook Sales rebounded and grew 49 percent to $1.4 billion; underlying1 sales grew 44 percent TAVR sales exceeded expectations and grew 52 percent; underlying sales grew 48 percent EPS […]
Craig Granowitz, M.D., Ph.D. Joins Lexicon as Senior Vice President and Chief Medical Officer
THE WOODLANDS, Texas, July 30, 2021 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that Craig Granowitz, M.D., Ph.D. will join the company as senior vice president and chief medical officer, effective August 2, 2021. Dr. Granowitz joins Lexicon with deep and successful leadership experience in the pharmaceutical industry, having […]
Tenaya Therapeutics Announces Pricing of Upsized Initial Public Offering
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, announced today the pricing of its underwritten, upsized initial public offering of 12,000,000 shares of its common stock at an […]
Cardinal Health completes sale of Cordis business to Hellman & Friedman
DUBLIN, Ohio, Aug. 2, 2021 /PRNewswire/ — Cardinal Health (NYSE: CAH) and Hellman & Friedman (H&F) announced today the completion of the previously announced sale of Cardinal Health’s Cordis business to H&F. The sale price of approximately $1 billion includes the buyer’s assumption of certain liabilities and the seller’s retention of certain working capital accounts. […]



